Global Metastatic Colorectal Cancer Market Report

Market Research Report

A quick peek into the report

1.1   Market Overview
1.1.1   Colorectal Cancer
1.1.2   Prevalence of Colorectal Cancer
1.1.3   Risk Factors of Colorectal Cancer
1.1.4   Symptoms
1.1.5   Key Risk Factors
1.1.6   Metastatic Colorectal Cancer
1.1.7   Stages of Metastatic Colorectal Cancer
1.1.8   Flowchart Depicting Treatment Options for mCRC Based on Tumor Mutational Status
1.1.9   Diagnosis and Treatment for Metastatic Colorectal Cancer
1.2   Epidemiological Analysis of Metastatic Colorectal Cancer
1.3   Regulatory Landscape of Global Metastatic Colorectal Cancer Market
1.3.1   Legal Requirement and Framework in U.S.
1.3.1.1   Responsible Agencies and Jurisdiction
1.3.1.2   Preclinical to Clinical: Submissions Required
1.3.1.3   Key Approval Pathways and Programs
1.3.1.4   Companion Diagnostics and Biomarker Considerations
1.3.1.5   Clinical Endpoints, Evidence Expectations, and Confirmatory Requirements
1.3.1.6   Post-Marketing Obligations and Label Expansion
1.3.1.7   Practical Implications for mCRC Sponsors (U.S.)
1.3.2   Legal Requirement and Framework in E.U.
1.3.2.1   Preclinical to Clinical Development
1.3.2.2   Marketing Authorization
1.3.2.3   Expedited and Conditional Pathways
1.3.2.4   Companion Diagnostics and Biomarkers
1.3.2.5   Post-Marketing Requirements
1.4   Market Trends
1.4.1   Trends: Current and Future Impact Assessment, 2024-2035
1.4.2   Market Trends
1.4.2.1   Emergence of Novel Targeted Agents
1.4.2.2   Clinical Research and Trials: Growing Focus in Metastatic Colorectal Cancer (mCRC)
1.5   Clinical Trials
1.6   Market Dynamics
1.6.1   Drivers, Challenges, and Opportunities: Current and Future Impact Assessment, 2024-2035
1.6.2   Market Drivers
1.6.2.1   Increasing Incidences of Metastatic Colorectal Cancer
1.6.2.2   Rising Use of Biologics/Biosimilars and Higher Approval Rates
1.6.3   Market Restraints
1.6.3.1   Adverse Effects of Cancer Drug Therapy
1.6.3.2   High Costs of Treatment
1.6.4   Market Opportunities
1.6.4.1   Developing Healthcare Infrastructure in Emerging Economies

2.1   Anti-Epidermal Growth Factor Receptor (EGFR) Inhibitors
2.2   Anti-Vascular Endothelial Growth Factor (VEGF) Therapies
2.3   Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapies
2.4   Immune Checkpoint Inhibitors
2.5   Other Therapies

3.1   North America
3.1.1   Regional Overview
3.1.2   Driving Factors for Market Growth
3.1.3   Factors Challenging the Market
3.1.4   Market Sizing and Forecast
3.1.4.1   North America Metastatic Colorectal Cancer Market (by Country)
3.1.5   U.S.
3.1.5.1   Country Overview
3.1.5.1.1   Market Sizing and Forecast
3.2   Europe
3.2.1   Regional Overview
3.2.2   Driving Factors for Market Growth
3.2.3   Factors Challenging the Market
3.2.4   Market Sizing and Forecast
3.2.5   Germany
3.2.5.1   Country Overview
3.2.5.1.1   Market Sizing and Forecast
3.2.6   U.K.
3.2.6.1   Country Overview
3.2.6.1.1   Market Sizing and Forecast
3.2.7   France
3.2.7.1   Country Overview
3.2.7.1.1   Market Sizing and Forecast
3.2.8   Italy
3.2.8.1   Country Overview
3.2.8.1.1   Market Sizing and Forecast
3.2.9   Spain
3.2.9.1   Country Overview
3.2.9.1.1   Market Sizing and Forecast
3.3   Asia-Pacific
3.3.1   Regional Overview
3.3.2   Driving Factors for Market Growth
3.3.3   Factors Challenging the Market
3.3.4   Market Sizing and Forecast
3.3.5   Japan
3.3.5.1   Country Overview
3.3.5.1.1   Market Sizing and Forecast

4.1   Key Strategies and Developments (by Company)
4.1.1   Funding Activities
4.1.2   Mergers and Acquisitions
4.1.3   Regulatory Approvals and Product Launches
4.1.4   Partnerships, Collaborations, and Business Expansions
4.2   Company Profiles
4.2.1   Amgen Inc.
4.2.1.1   Overview
4.2.1.2   Top Products/Product Portfolio
4.2.1.3   Top Competitors
4.2.1.4   Target Customers
4.2.1.5   Key Personal
4.2.1.6   Analyst View
4.2.2   Pfizer Inc.
4.2.2.1   Overview
4.2.2.2   Top Products/Product Portfolio
4.2.2.3   Top Competitors
4.2.2.4   Target Customers
4.2.2.5   Key Personal
4.2.2.6   Analyst View
4.2.3   Eli Lilly and Company
4.2.3.1   Overview
4.2.3.2   Top Products/Product Portfolio
4.2.3.3   Top Competitors
4.2.3.4   Target Customers
4.2.3.5   Key Personal
4.2.3.6   Analyst View
4.2.4   Sanofi
4.2.4.1   Overview
4.2.4.2   Top Products/Product Portfolio
4.2.4.3   Top Competitors
4.2.4.4   Target Customers
4.2.4.5   Key Personal
4.2.4.6   Analyst View
4.2.5   Merck KGaA
4.2.5.1   Overview
4.2.5.2   Top Products/Product Portfolio
4.2.5.3   Top Competitors
4.2.5.4   Target Customers
4.2.5.5   Key Personal
4.2.5.6   Analyst View
4.2.6   Takeda Pharmaceutical Company Limited
4.2.6.1   Overview
4.2.6.2   Top Products/Product Portfolio
4.2.6.3   Top Competitors
4.2.6.4   Target Customers
4.2.6.5   Key Personal
4.2.6.6   Analyst View
4.2.7   Taiho Oncology, Inc.
4.2.7.1   Overview
4.2.7.2   Top Products/Product Portfolio
4.2.7.3   Top Competitors
4.2.7.4   Target Customers
4.2.7.5   Key Personal
4.2.7.6   Analyst View
4.2.8   Bristol-Myers Squibb Company
4.2.8.1   Overview
4.2.8.2   Top Products/Product Portfolio
4.2.8.3   Top Competitors
4.2.8.4   Target Customers
4.2.8.5   Key Personal
4.2.8.6   Analyst View
4.2.9   Johnson & Johnson
4.2.9.1   Overview
4.2.9.2   Top Products/Product Portfolio
4.2.9.3   Top Competitors
4.2.9.4   Target Customers
4.2.9.5   Key Personal
4.2.9.6   Analyst View
4.2.10   Shanghai Henlius Biotech, Inc.
4.2.10.1   Overview
4.2.10.2   Top Products/Product Portfolio
4.2.10.3   Top Competitors
4.2.10.4   Target Customers
4.2.10.5   Key Personal
4.2.10.6   Analyst View
4.2.11   Treos Bio Limited
4.2.11.1   Overview
4.2.11.2   Top Products/Product Portfolio
4.2.11.3   Top Competitors
4.2.11.4   Target Customers
4.2.11.5   Key Personal
4.2.11.6   Analyst View
4.2.12   Inspirna Inc.
4.2.12.1   Overview
4.2.12.2   Top Products/Product Portfolio
4.2.12.3   Top Competitors
4.2.12.4   Target Customers
4.2.12.5   Key Personal
4.2.12.6   Analyst View
4.2.13   Bayer AG
4.2.13.1   Overview
4.2.13.2   Top Products/Product Portfolio
4.2.13.3   Top Competitors
4.2.13.4   Target Customers
4.2.13.5   Key Personal
4.2.13.6   Analyst View

5.1   Data Sources
5.1.1   Primary Data Sources
5.1.2   Secondary Data Sources
5.1.3   Data Triangulation
5.2   Market Estimation and Forecast

Table 1:   Market Snapshot
Table 2:   Number of mCRC Cases (Thousands), by Major Countries, 2022-2025
Table 3:   U.S. Regulatory Framework for Metastatic Colorectal Cancer Therapeutics
Table 4:   European Union Regulatory Framework for Metastatic Colorectal Cancer Therapeutics
Table 5:   Recent Approvals of Metastatic Colorectal Cancer Drugs
Table 6:   Side Effects Caused by Common Metastatic Cancer Drugs

Figure 1:   Global Metastatic Colorectal Cancer Market (by Scenario), $Billion, 2024, 2030, and 2035
Figure 2:   Key take aways for the Global Metastatic Colorectal Cancer Market
Figure 3:   Overview of Market Dynamics of Global Metastatic Colorectal Cancer Market
Figure 4:   Global Metastatic Colorectal Cancer Market (by Region), $Billion, 2024 and 2035
Figure 5:   Global Metastatic Colorectal Cancer Market (by Drug Class), $Billion, 2024, 2030, and 2035
Figure 6:   Selected Ongoing Clinical Trials in Metastatic Colorectal Cancer (by Phase)
Figure 7:   Global Metastatic Colorectal Cancer Market (Anti-Epidermal Growth Factor Receptor (EGFR) Inhibitors), $Billion, 2024 -2035
Figure 8:   Global Metastatic Colorectal Cancer Market (Anti-Vascular Endothelial Growth Factor (VEGF) Therapies), $Billion, 2024-2035
Figure 9:   Global Metastatic Colorectal Cancer Market (Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapies), $Billion, 2024-2035
Figure 10:   Global Metastatic Colorectal Cancer Market (Immune Checkpoint Inhibitors), $Billion, 2024-2035
Figure 11:   Global Metastatic Colorectal Cancer Market (Other Therapies), $Billion, 2024-2035
Figure 12:   North America Metastatic Colorectal Cancer Market, $Billion, 2024-2035
Figure 13:   U.S. Metastatic Colorectal Cancer Market, $Billion, 2024-2035
Figure 14:   Europe Metastatic Colorectal Cancer Market, $Billion, 2024-2035
Figure 15:   Germany Metastatic Colorectal Cancer Market, $Billion, 2024-2035
Figure 16:   U.K. Metastatic Colorectal Cancer Market, $Billion, 2024-2035
Figure 17:   France Metastatic Colorectal Cancer Market, $Billion, 2024-2035
Figure 18:   Italy Metastatic Colorectal Cancer Market, $Billion, 2024-2035
Figure 19:   Spain Metastatic Colorectal Cancer Market, $Billion, 2024-2035
Figure 20:   Asia-Pacific Metastatic Colorectal Cancer Market, $Billion, 2024-2035
Figure 21:   Japan Metastatic Colorectal Cancer Market, $Billion, 2024-2035
Figure 22:   Data Triangulation
Figure 23:   Top-Down and Bottom-Up Approach
Figure 24:   Assumptions and Limitations

Metastatic Colorectal Cancer Market Report Coverage

Metastatic Colorectal Cancer Market
Base Year	2024	Market Size in 2024	$6.78 Billion
Forecast Period	2025-2035	Value Projection and Estimation by 2035	$19.06 Billion
CAGR During Forecast Period	9.75%	Number of Pages	84
Number of Tables	6	Number of Figures	24

Key Market Players and Competitive Landscape

The global metastatic colorectal cancer market is characterized by a rapidly evolving and competitive landscape, driven by technological innovation, strategic partnerships, and the growing demand for next-generation therapeutics. The market comprises a mix of well-established biopharmaceutical companies and emerging biotechnology firms specializing in chemotherapies, immune=targeted therapies, and targeted therapies for metastatic colorectal cancer. Key players include:

•   Amgen Inc.
•   Bayer AG
•   Bristol-Myers Squibb Company
•   Eli Lilly and Company
•   Inspirna Inc.
•   Johnson & Johnson
•   Merck KGaA
•   Pfizer Inc.
•   Sanofi
•   Shanghai Henlius Biotech, Inc.
•   Taiho Oncology, Inc.
•   Takeda Pharmaceutical Company Limited
•   Treos Bio Limited

Competitive benchmarking highlights mergers and acquisitions, funding activities, licensing deals, and collaborations with pharmaceutical organizations, reflecting the growing emphasis on innovation and speed-to-market. Companies are evaluated based on market presence, technological capabilities, strategic initiatives, and product portfolios. Detailed company profiles cover target end users, technological focus areas, and expert analyst perspectives, providing stakeholders with actionable insights into investment opportunities, market positioning, and strategic growth pathways. This intelligence enables organizations to effectively align their R&D and commercialization strategies with emerging market dynamics of the global metastatic colorectal cancer market.

How can this report add value to an organization?

Product/Innovation: This report enables organizations to identify high-value opportunities in the global metastatic colorectal cancer market, with a focus on innovation-driven growth across various drug classes. It supports strategic R&D decision-making by guiding investment prioritization, technology integration, and clinical pipeline optimization. The insights provided help stakeholders accelerate biomarker-based therapy development, optimize clinical trial designs, and strengthen innovation capabilities to improve treatment efficacy and patient outcomes.

Growth/Marketing: The report delivers in-depth insights into regional treatment adoption patterns, reimbursement environments, and accessibility challenges, supporting informed market expansion and commercialization planning. Organizations can identify growth potential across drug classes. By understanding regional disease burden, healthcare investment trends, and evolving regulatory frameworks, companies can refine market entry strategies, enhance physician and patient engagement, and strengthen commercialization and partnering initiatives in both established and emerging markets.

Competitive: This report provides comprehensive company profiling, competitive benchmarking, highlighting strategic collaborations, funding activities, mergers, acquisitions, and drug launch. Stakeholders gain a clear understanding of competitor focus areas, R&D priorities, and market positioning. This intelligence allows organizations to identify gaps, anticipate market shifts, and formulate strategies to differentiate themselves, optimize market entry, and maintain leadership in the metastatic colorectal cancer therapy ecosystem.

Global Metastatic Colorectal Cancer Market: Industry Overview

The global metastatic colorectal cancer market is projected to reach $19.06 billion by 2035 from $6.78 billion in 2024, growing at a CAGR of 9.75% during the forecast period 2025-2035. The global metastatic colorectal cancer market is experiencing strong growth driven by the rising global incidence of colorectal cancer and the increasing number of patients progressing to advanced disease stages. The shift toward personalized medicine, biomarker-driven treatment strategies, and combination therapy approaches has significantly improved clinical outcomes compared to traditional chemotherapy alone. Advancements in targeted therapy, immuno-oncology, and precision medicine continue to reshape treatment protocols, particularly for patients with specific genetic alterations such as MSI-H/dMMR, BRAF V600E, or KRAS mutations. With projections indicating a substantial rise in colorectal cancer cases by 2040, demand for effective metastatic treatment options is expected to accelerate.

Biologics and biosimilars are playing a key role in expanding treatment access while improving survival rates and disease management, supported by higher regulatory approval activity and robust late-stage development pipelines. However, challenges including high treatment costs, therapy-associated toxicities, and limited accessibility in low-resource regions are expected to hinder the growth of the global metastatic colorectal cancer market. As healthcare infrastructure improves in emerging economies and pricing models evolve, broader adoption of advanced therapies is expected. Overall, the metastatic colorectal cancer market is positioned for continued expansion, driven by innovation, rising patient need, and increasing global focus on improving survival and quality of life for patients with metastatic disease.

Global Metastatic Colorectal Cancer Market Lifecycle Stage

The global metastatic colorectal cancer market is currently in a growth stage of its lifecycle, supported by continued innovation, increasing treatment adoption, and a rising global disease burden. The market has moved beyond early development, where treatment options were limited primarily to chemotherapy, and is now characterized by expanding therapeutic diversity, including targeted therapies, immunotherapies, biologics, and biomarker-guided regimens. Regulatory bodies across major healthcare markets are actively approving new therapies and indications, demonstrating a high level of research momentum and investment. The increasing focus on precision medicine and molecular profiling further indicates that the market is evolving toward more personalized and effective treatment pathways.

As the market progresses, competition is intensifying, pipelines remain strong, and biosimilars are beginning to contribute to broader access and cost optimization. However, the market has not yet reached saturation, as unmet needs persist in areas such as treatment resistance, long-term safety, and access in lower-income regions. Continued expansion into emerging markets, combination therapy advancements, and improvements in reimbursement frameworks are expected to support sustained growth.

Figure: Global Metastatic Colorectal Cancer Market Snapshot

Market Segmentation:

Segmentation 1: By Drug Class
•   Anti-EGFR Inhibitors
•   Anti-VEGF Therapies
•   Anti-HER2 Therapies
•   Immune Checkpoint Inhibitors
•   Other Therapies

The other therapies segment represents the largest segment of the metastatic colorectal cancer market as it includes traditional chemotherapies with emerging targeted agents such as KRAS and BRAF inhibitors. The combination of high utilization (chemotherapies) and concentrated pricing in niche targets makes this segment larger other narrowly defined classes.

Segmentation 2: By Region
•   North America
•   Europe
•   Asia-Pacific

North America captures the largest regional share, underpinned by the U.S. market’s premium pricing, rapid uptake of novel biologics and immunotherapies, and broad reimbursement coverage. Compared with Europe and Japan, the U.S. demonstrates both higher treatment penetration and earlier access to innovative drugs, which translates into a larger revenue contribution relative to patient numbers.

Demand – Drivers and Limitations

Demand Drivers for the Global Metastatic Colorectal Cancer Market:

• Increasing Incidences of Metastatic Colorectal Cancer
• Rising Use of Biologics/Biosimilars and Higher Approval Rates

Limitations for the Global Metastatic Colorectal Cancer Market:

• Adverse Effects of Cancer Drug Therapy
• High Costs of Treatment

Metastatic Colorectal Cancer Market - A Global and Regional Analysis

Focus on Drug Class and Country - Analysis and Forecast, 2025-2035

Get Free Sample

Schedule a Call

Some Faq's

Frequently Asked Questions

Metastatic colorectal cancer is an advanced stage of colorectal cancer in which malignant cells spread beyond the colon or rectum to distant organs such as the liver, lungs, or lymph nodes. This stage typically indicates a more aggressive form of the disease and often requires multimodal treatment approaches, including chemotherapy, targeted therapy, immunotherapy, and supportive care.

The growth of the global metastatic colorectal cancer market is driven by the rising global incidence of colorectal cancer, advancements in precision medicine and targeted therapies, increasing adoption of biologics and immunotherapies, and growing availability of biomarker-driven treatment approaches. Additionally, expanding clinical research pipelines and increasing regulatory approvals continue to support market expansion.

Key challenges that are expected to hinder the growth of the global metastatic colorectal cancer market include high treatment costs, limited accessibility in low- and middle-income regions, and significant treatment-related side effects that impact patient adherence and quality of life. Additionally, resistance to existing therapies and the need for improved long-term survival outcomes remain major barriers in advancing care for metastatic colorectal cancer.

This report offers a comprehensive, end-to-end analysis of the global metastatic colorectal cancer market, combining market sizing, growth forecasts, competitive intelligence, and drug class insights. It emphasizes emerging innovations, including AI integration. In addition, the report includes extensive company profiling, benchmarking, funding analysis, partnership tracking, clinical trial analysis, equipping stakeholders with actionable insights for strategic decision-making. Its value lies in integrating technological developments with commercial and competitive intelligence, supporting informed choices regarding R&D prioritization, market entry, and partnership strategies.

This report is intended for biopharmaceutical companies, biotechnology firms, and organizations involved in developing targeted therapies, immunotherapies, biologics, biosimilars, and precision medicine solutions for metastatic colorectal cancer. It will also benefit CROs, CDMOs, academic and clinical research institutions, and technology providers supporting oncology drug discovery, biomarker testing, companion diagnostics, and clinical trial execution. Additionally, investors, venture capital firms, healthcare strategists, and policy decision-makers can leverage these insights to evaluate market opportunities, assess partnerships, and align investment priorities with emerging trends such as immuno-oncology advancements, personalized therapy development, and the growing adoption of combination and biomarker-driven treatment approaches in the metastatic colorectal cancer landscape.

Colorectal Cancer Screening and Diagnostics Market - A Global and Regional Analysis: Focus on Type,

The global colorectal cancer screening and diagnostics market was valued at $38,540.7 million...

View Report

Published Year: 2018

Global Metastatic Cancer Treatment Market : Focus on Drugs, Competitive Landscape, and Country - Ana

The global metastatic cancer treatment market was valued $54.11 billion in 2017, and is...

View Report

A quick peek into the report

Table of Contents

Metastatic Colorectal Cancer Market Report Coverage

How can this report add value to an organization?

Global Metastatic Colorectal Cancer Market: Industry Overview

$4900

Metastatic Colorectal Cancer Market - A Global and Regional Analysis

Frequently Asked Questions

You may also like

Colorectal Cancer Screening and Diagnostics Market - A Global and Regional Analysis: Focus on Type,

Global Metastatic Cancer Treatment Market : Focus on Drugs, Competitive Landscape, and Country - Ana

Metastatic Colorectal Cancer Market - A Global and Regional Analysis

A quick peek into the report

Table of Contents

1 Market: Industry Outlook

2 Drug Class

3 Region

4 Markets - Competitive Benchmarking and Company Profiles

5 Research Methodology

List of Tables

List of Figures

Metastatic Colorectal Cancer Market Report Coverage

How can this report add value to an organization?

Global Metastatic Colorectal Cancer Market: Industry Overview

$4900

Metastatic Colorectal Cancer Market - A Global and Regional Analysis

Frequently Asked Questions

Q: What is metastatic colorectal cancer?

Q: What is driving the growth of the global metastatic colorectal cancer market?

Q: What are the challenges faced by the global metastatic colorectal cancer market?

Q: What is the USP of this report?

Q: Who should buy this report?

You may also like

Colorectal Cancer Screening and Diagnostics Market - A Global and Regional Analysis: Focus on Type,

Global Metastatic Cancer Treatment Market : Focus on Drugs, Competitive Landscape, and Country - Ana